Sector News

Protagen AG Appoints Bernhard Kirschbaum as New Chairman

July 22, 2016
Life sciences

Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company’s Supervisory Board.

Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.

Dr. Schacht successfully completed the IPO of Curetis in November last year, and served previously in executive positions at Epigenomics Inc. Seattle WA, USA and Epigenomics AG, Berlin. He is a member of the Executive Board of BioDeutschland and has a proven track record in the diagnostics industry, with a strong network in the international capital markets, business development, and sales. “Protagen has recently launched its first proprietary CE-IVD marked products and the Protagen platform is able to continuously deliver novel, clinically validated biomarkers in a market that is in need of novel content,” said Dr. Schacht. “I look forward to supporting the management team and board in translating their efforts into a sustainable commercial success.”

Stefan Müllner, CEO of Protagen, added: “Having successfully executed two IPOs in the diagnostic field, Oliver Schacht will provide invaluable guidance for an effective and targeted expansion of our business.”

Bernhard Kirschbaum, new Chairman of the Protagen Board, commented: “I would like to welcome Oliver Schacht in his new role. Oliver is a great addition to the Board and will help us to grow the business in the demanding field of autoimmune diagnostics. Having served as Chairman of the Board for the last 15 years, Axel Kleemann was the key person who shaped Protagen. We would like to sincerely thank him for his long standing commitment and guidance and I am truly sad to see him leave.”

Source: Protagen

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach